{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:03:00Z","timestamp":1761238980311,"version":"build-2065373602"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.critrevonc.2022.103707","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T03:08:12Z","timestamp":1652411292000},"page":"103707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology"],"prefix":"10.1016","volume":"175","author":[{"given":"Elena","family":"Muraro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Roman\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fanetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Vaccher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Turturici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Lupato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Biagio","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Polesel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Fratta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Giacomarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Franchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Steffan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2022.103707_bib1","doi-asserted-by":"crossref","unstructured":"Alam M, Ratner D. Cutaneous Squamous-Cell Carcinoma. http:\/\/dx.doi.org\/101056\/NEJM200103293441306. 2009;344(13):975-983. doi:10.1056\/NEJM200103293441306.","DOI":"10.1056\/NEJM200103293441306"},{"key":"10.1016\/j.critrevonc.2022.103707_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"5-6","key":"10.1016\/j.critrevonc.2022.103707_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000502325","article-title":"High-grade neuroendocrine carcinoma of the head and neck: Human papillomavirus status and pd-l1 expression","volume":"81","author":"Bahr","year":"2019","journal-title":"ORL"},{"key":"10.1016\/j.critrevonc.2022.103707_bib4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1: PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib5","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3389\/fimmu.2019.01644","article-title":"TLR9 mediated tumor-stroma interactions in Human Papilloma Virus (HPV)-positive head and neck squamous cell carcinoma up-regulate PD-L1 and PD-L2","volume":"10","author":"Baruah","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103707_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/PAI.0000000000000590","article-title":"Expression of PD-L1 on immune cells shows better prognosis in laryngeal, oropharygeal, and hypopharyngeal cancer","volume":"26","author":"Birtalan","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103707_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11070651","article-title":"The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: a Pilot Study","volume":"11","author":"Botticelli","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.critrevonc.2022.103707_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/IOP.0000000000001472","article-title":"The programmed death pathway in ocular adnexal sebaceous carcinoma","volume":"Vol 36","author":"Bowen","year":"2020","journal-title":"Ophthalm. Plastic Reconstruct. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib10","first-page":"1015","article-title":"Soluble programmed death receptor ligands sPD-L1 and sPD-L2 as liquid biopsy markers for prognosis and platinum response in epithelial ovarian cancer","volume":"9","author":"Buderath","year":"2019"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103707_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1392427","article-title":"Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma","volume":"7","author":"Cao","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s42003-019-0352-3","article-title":"Dynamic host immune response in virus-associated cancers","volume":"2","author":"Cao","year":"2019","journal-title":"Commun. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","article-title":"PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2","volume":"32","author":"Carter","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib14","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2147\/OTT.S134589","article-title":"Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors","volume":"10","author":"Chang","year":"2017","journal-title":"Oncol\/ Targets Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103707_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12105-020-01229-w","article-title":"Transcriptomic and immunophenotypic characterization of tumor immune microenvironment in squamous cell carcinoma of the oral tongue","volume":"15","author":"Chatzopoulos","year":"2021","journal-title":"Head Neck Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103707_bib16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nri1349","article-title":"Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity","volume":"4","author":"Chen","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"10192","key":"10.1016\/j.critrevonc.2022.103707_bib17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet)"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.oraloncology.2018.12.002","article-title":"Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma","volume":"89","author":"Chikamatsu","year":"2019","journal-title":"Oral Oncol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib20","doi-asserted-by":"crossref","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ K-040 investigators, Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro Jr G, Psyrri A, Bast\u00e9 N, Neupane P, Bratland \u00c5, Fuereder T, Hughes BGM, Mes\u00eda R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Gonz\u00e1lez Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, J K-048 I. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;394(10212):1915-1928. doi:10.1016\/S0140-6736(19)32591-7.","DOI":"10.1016\/S0140-6736(19)32591-7"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103707_bib21","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/annonc\/mdy411","article-title":"Safety and clinical activity of atezolizumab in head and neck cancer: Results from a phase I trial","volume":"29","author":"Colevas","year":"2018","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103707_bib22","article-title":"Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab","volume":"7","author":"Costantini","year":"2018","journal-title":"Oncoimmunology"},{"issue":"48","key":"10.1016\/j.critrevonc.2022.103707_bib23","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1607836113","article-title":"Association of PD-1\/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors","volume":"113","author":"Danilova","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103707_bib24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/2326-6066.CIR-15-0046","article-title":"Epithelial PD-L2 expression marks Barrett\u2019s esophagus and esophageal Adenocarcinoma","volume":"3","author":"Derks","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103707_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/imt-2020-0037","article-title":"DNA methylation in papillary thyroid carcinoma","volume":"12","author":"De","year":"2020","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1172\/JCI16015","article-title":"Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis","volume":"111","author":"Dong","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2022.103707_bib27","unstructured":"EEWC., D. S, C. LT, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. 2019;393(10167):156-167. doi:10.1016\/S0140-6736, 18, 31999-8."},{"key":"10.1016\/j.critrevonc.2022.103707_bib28","unstructured":"EI-Naggar A.K., Chan J.K.C., Grandis J.R., Takata T. SP. WHO Classification of Head and Neck Tumours.; 2017."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103707_bib29","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2008-0607","article-title":"BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103707_bib30","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.4049\/jimmunol.1000810","article-title":"APCs expressing high levels of programmed death ligand 2 sustain the development of CD4 T cell memory","volume":"185","author":"Ellis","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2022.103707_bib31","unstructured":"FDA Approves Libtayo\u00ae (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma | Regeneron Pharmaceuticals Inc. Accessed January 6, 2022. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-libtayor-cemiplimab-rwlc-first-and-only-treatment\/."},{"key":"10.1016\/j.critrevonc.2022.103707_bib32","doi-asserted-by":"crossref","unstructured":"Ferris R.L., Blumenschein Jr G., Fayette J., Guigay J., Colevas A.D., Licitra L., Harrington K.J., Kasper S., Vokes E.E., Even C., Worden F., Saba N.F., Iglesias Docampo L.C., Haddad R., Rordorf T., Kiyota N., Tahara M., Lynch M., Jayaprakash V., Li L.G.M. Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. 2018;81:45-51. doi:10.1016\/j.oraloncology.2018.04.008.","DOI":"10.1016\/j.oraloncology.2018.04.008"},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103707_bib33","first-page":"36434","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"S0923-7534","author":"Ferris","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib34","first-page":"e349","article-title":"A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer","volume":"18","author":"Floudas","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.18632\/oncotarget.23080","article-title":"PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas","volume":"9","author":"Franzen","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103707_bib36","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103707_bib37","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.40164","article-title":"Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.21873\/anticanres.14755","article-title":"Clinicopathological and prognostic analysis of PD-L1 and PD-L2 expression in surgically resected primary tongue squamous cell carcinoma","volume":"41","author":"Furukawa","year":"2021","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103707_bib39","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.humimm.2014.01.011","article-title":"Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance","volume":"75","author":"Gaur","year":"2014","journal-title":"Hum. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103707_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1460298","article-title":"PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab","volume":"7","author":"George","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2022.103707_bib42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103707_bib43","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1111\/j.1600-6143.2007.01999.x","article-title":"Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4+ and CD8+ T cells in vivo","volume":"7","author":"Habicht","year":"2007","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103707_bib44","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103707_bib45","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1707","article-title":"Central tolerance: learning self-control in the thymus","volume":"5","author":"Hogquist","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib46","first-page":"1","article-title":"Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy","volume":"13","author":"Ishitsuka","year":"2021"},{"key":"10.1016\/j.critrevonc.2022.103707_bib47","first-page":"5225","article-title":"Currently Used Laboratory Methodologies for Assays Detecting Pd\u20101, Pd\u2010l1, Pd\u2010l2 and Soluble Pd\u2010l1 in Patients with Metastatic Breast Cancer","volume":"13","author":"Jeong","year":"2021"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/cei.12921","article-title":"Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells","volume":"188","author":"Jiao","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.651634","article-title":"Soluble B7-CD28 family inhibitory immune checkpoint proteins and anti-cancer immunotherapy","volume":"12","author":"Khan","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103707_bib50","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/cncr.26500","article-title":"The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib51","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.21873\/anticanres.11465","article-title":"Pd-l1 expression confers better prognosis in locally advanced oral squamous cell carcinoma","volume":"37","author":"Kogashiwa","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2022.103707_bib52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2020.00268","article-title":"Current understanding of the mechanisms underlying immune evasion from PD-1\/PD-L1 immune checkpoint blockade in head and neck cancer","volume":"10","author":"Kok","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032145","article-title":"The axonal guidance receptor neogenin promotes acute inflammation","volume":"7","author":"K\u00f6nig","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"issue":"30","key":"10.1016\/j.critrevonc.2022.103707_bib55","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.0804453105","article-title":"Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2","volume":"105","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib56","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/mi.2012.111","article-title":"PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production","volume":"6","author":"Lewkowich","year":"2013","journal-title":"Mucosal. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103707_bib57","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","author":"Liang","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib58","unstructured":"Libtayo | European Medicines Agency. Accessed January 6, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libtayo."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103707_bib59","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-020-01818-1","article-title":"PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2\/Ras\/MAPK signalling in thyroid cancer cells","volume":"40","author":"Liotti","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103707_bib61","first-page":"92","article-title":"The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer","author":"Liu","year":"2021","journal-title":"Phytomedicine"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103707_bib62","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1084\/jem.20022089","article-title":"B7DC\/PDL2 promotes tumor immunity by a PD-1-independent mechanism","volume":"197","author":"Liu","year":"2003","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13000-015-0297-x","article-title":"Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer","volume":"10","author":"Li","year":"2015","journal-title":"Diagn. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103707_bib64","first-page":"544","article-title":"Repulsive guidance molecules, novel bone morphogenetic protein co-receptors, are key regulators of the growth and aggressiveness of prostate cancer cells","volume":"40","author":"Li","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103707_bib65","doi-asserted-by":"crossref","first-page":"15678","DOI":"10.18632\/oncotarget.7463","article-title":"Repulsive guidance molecule B inhibits metastasis and is associated with decreased mortality in non-small cell lung cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103707_bib66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1440-1711.2002.01068.x","article-title":"Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack","volume":"80","author":"Maher","year":"2002","journal-title":"Immunol. Cell Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib67","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.4049\/jimmunol.172.4.2530","article-title":"B7-DC regulates asthmatic response by an IFN-\u03b3-dependent mechanism","volume":"172","author":"Matsumoto","year":"2004","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103707_bib68","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.4049\/jimmunol.1700555","article-title":"PD-L2 regulates B-1 cell antibody production against phosphorylcholine through an IL-5\u2013dependent mechanism","volume":"199","author":"McKay","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib69","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103707_bib70","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/hed.25713","article-title":"Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma","volume":"41","author":"Moratin","year":"2019","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ejh.13621","article-title":"Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies","volume":"107","author":"Mortensen","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib72","first-page":"88","article-title":"Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands","author":"Mosconi","year":"2019","journal-title":"Oral Oncol."},{"issue":"32","key":"10.1016\/j.critrevonc.2022.103707_bib73","doi-asserted-by":"crossref","first-page":"52889","DOI":"10.18632\/oncotarget.17547","article-title":"PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma","volume":"8","author":"M\u00fcller","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103707_bib74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.oraloncology.2019.01.015","article-title":"Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas","volume":"90","author":"Nakano","year":"2019","journal-title":"Oral Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103707_bib75","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.4049\/jimmunol.178.9.5552","article-title":"Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells","volume":"178","author":"Nazareth","year":"2007","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","article-title":"The PD-1-PD-L pathway in immunological tolerance","volume":"27","author":"Okazaki","year":"2006","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103707_bib77","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/eji.200535344","article-title":"No evidence for dualism in function and receptors: PD-L2\/B7-DC is an inhibitory regulator of human T cell activation","volume":"36","author":"Pfistershammer","year":"2006","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib78","doi-asserted-by":"crossref","first-page":"1947569","DOI":"10.1080\/2162402X.2021.1947569","article-title":"PD-L2 based immune signature confers poor prognosis in HNSCC","volume":"10","author":"Qiao","year":"2021","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103707_bib79","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103707_bib80","first-page":"1015","article-title":"PD-1\/PD-L1, PD-1\/PD-L2, and other co-inhibitory signaling pathways in transplantation","volume":"21","author":"Del Rio","year":"2008","journal-title":"Transpl. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib83","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1189\/jlb.0610327","article-title":"Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10","volume":"89","author":"Rodriguez-Garcia","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib84","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","author":"Rozali","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib85","doi-asserted-by":"crossref","first-page":"3939720","DOI":"10.1155\/2019\/3939720","article-title":"Analysis of plasma EBV-DNA and soluble checkpoint proteins in nasopharyngeal carcinoma patients after definitive intensity-modulated radiotherapy","volume":"2019","author":"Ruan","year":"2019","journal-title":"Biomed. Res. Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib86","first-page":"1343","article-title":"Squamous cell carcinoma antigen-encoding genes serpinb3\/b4 as potentially useful markers for the stratification of hnscc tumours","volume":"38","author":"Saidak","year":"2018","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1084\/jem.20022119","article-title":"Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis","volume":"198","author":"Salama","year":"2003","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103707_bib88","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/jop.12722","article-title":"The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma","volume":"47","author":"Sato","year":"2018","journal-title":"J. Oral. Pathol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijrobp.2018.05.002","article-title":"Evaluating the PD-1 axis and immune effector cell infiltration in oropharyngeal squamous cell carcinoma","volume":"102","author":"Schoenfeld","year":"2018","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103707_bib91","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1084\/jem.20050072","article-title":"In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses","volume":"201","author":"Shin","year":"2005","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103707_bib92","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103707_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100811","article-title":"Programmed cell death-ligand 2: a neglected but important target in the immune response to cancer?","volume":"13","author":"Solinas","year":"2020","journal-title":"Transl Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103707_bib94","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2326-6066.CIR-16-0031","article-title":"Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes","volume":"4","author":"Sridharan","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib95","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1158\/1535-7163.MCT-17-0504","article-title":"A correlative analysis of pd-l1, pd-1, pd-l2, EGFR, her2, and her3 expression in oropharyngeal squamous cell carcinoma","volume":"17","author":"Steuer","year":"2018","journal-title":"Mol. Cancer The.r"},{"key":"10.1016\/j.critrevonc.2022.103707_bib96","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"Vol 153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib97","unstructured":"Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov. Accesse 6 January, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02760498."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103707_bib98","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00262-020-02747-w","article-title":"Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas","volume":"70","author":"Succaria","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib99","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/cas.14336","article-title":"Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma","volume":"111","author":"Sudo","year":"2020","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103707_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/14728222.2020.1804863","article-title":"Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?","volume":"24","author":"Theocharis","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.critrevonc.2022.103707_bib101","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.imlet.2020.09.001","article-title":"Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity","volume":"227","author":"Tong","year":"2020","journal-title":"Immunol. Lett."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103707_bib102","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2022.103707_bib103","doi-asserted-by":"crossref","first-page":"1742951","DOI":"10.1155\/2018\/1742951","article-title":"CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers","volume":"2018","author":"Tuccilli","year":"2018","journal-title":"Int. J. Endocrinol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103707_bib104","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1084\/jem.20021752","article-title":"Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction","volume":"197","author":"Wang","year":"2003","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s40425-019-0810-y","article-title":"Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients","volume":"7","author":"Wang","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib106","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/cam4.1929","article-title":"Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma\u2014a comparison to the PD-L1 expression profile","volume":"8","author":"Weber","year":"2019","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103707_bib107","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jcms.2020.12.007","article-title":"PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood","volume":"49","author":"Wehrhan","year":"2021","journal-title":"J. Cranio-Maxillofacial Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103707_bib108","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103707_bib109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/vaccines4040035","article-title":"Tumor-derived exosomes and their role in tumor-induced immune suppression","volume":"4","author":"Whiteside","year":"2016","journal-title":"Vaccines"},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103707_bib110","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.3390\/ijms22179114","article-title":"Hypofractionated radiotherapy upregulates several immune checkpoint molecules in head and neck squamous cell carcinoma cells independently of the HPV status while ICOS-L Is upregulated only on HPV-positive cells","volume":"22","author":"Wimmer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2022.103707_bib111","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ajo.2018.12.020","article-title":"Programmed cell death 1 ligand 1 and programmed cell death 1 ligand 2 are expressed in conjunctival invasive squamous cell carcinoma: therapeutic implications","volume":"200","author":"Wolkow","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib112","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajo.2020.07.031","article-title":"High expression of programmed death ligand 1 and programmed death ligand 2 in ophthalmic sebaceous carcinoma: the case for a clinical trial of checkpoint inhibitors","volume":"220","author":"Wolkow","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib113","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/IOP.0000000000001585","article-title":"PD-L1 and PD-L2 expression levels are low in primary and secondary adenoid cystic carcinomas of the orbit: therapeutic implications","author":"Wolkow","year":"2020","journal-title":"Ophthal. Plast Reconstr. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103707_bib114","first-page":"1512","article-title":"Serum soluble PD-L1, PD-L2, and B7-H5 as potential diagnostic biomarkers of human pancreatic cancer","volume":"67","author":"Wu","year":"2021","journal-title":"Clin. Lab."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103707_bib115","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-l2 and its engagement with PD-l2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib116","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","article-title":"Association between BRAF V600E mutation and recurrence of papillary thyroid cancer","volume":"33","author":"Xing","year":"2015","journal-title":"J. Clin Oncol."},{"key":"10.1016\/j.critrevonc.2022.103707_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109222","article-title":"LncRNA RGMB-AS1 promotes laryngeal squamous cell carcinoma cells progression via sponging miR-22\/NLRP3 axis","volume":"118","author":"Xu","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02010-9","article-title":"Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer","volume":"40","author":"Yarza","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103707_bib119","first-page":"2021","article-title":"Transcutaneous carbon dioxide decreases immunosuppressive factors in squamous cell carcinoma in vivo","author":"Yatagai","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103707_bib120","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to Anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib121","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103707_bib122","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3803\/EnM.2020.35.1.44","article-title":"Recent improvements in genomic and transcriptomic understanding of anaplastic and poorly differentiated thyroid cancers","volume":"35","author":"Yoo","year":"2020","journal-title":"Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103707_bib123","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0006-291X(03)01257-9","article-title":"Differential binding properties of B7-H1 and B7-DC to programmed death-1","volume":"307","author":"Youngnak","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103707_bib124","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural BIology of the Immune Checkpoint Receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"issue":"31","key":"10.1016\/j.critrevonc.2022.103707_bib125","doi-asserted-by":"crossref","first-page":"11695","DOI":"10.1073\/pnas.0601347103","article-title":"Regulation of T cell activation and tolerance by PDL2","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103707_bib126","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.7150\/jca.43854","article-title":"MiR-93-5p enhances migration and invasion by targeting RGMB in squamous cell carcinoma of the head and neck","volume":"11","author":"Zhang","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103707_bib127","first-page":"9","article-title":"Characterization of molecular subtypes in head and neck squamous cell carcinoma with distinct prognosis and treatment responsiveness","author":"Zhang","year":"2021","journal-title":"Frony. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103707_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153093","article-title":"Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma","volume":"216","author":"Zhou","year":"2020","journal-title":"Pathol. Res. Pract."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:44:44Z","timestamp":1760903084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822001317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":128,"alternative-id":["S1040842822001317"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103707","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103707"}}